Skip to main content
SpringerLink
Log in

Giapreza cost effective for severe distributive shock

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2017 US dollars

References

  1. Nicholson G, et al. Giapreza for the Treatment of Severe Distributive Shock in the Intensive Care Unit: a US Cost-Effectiveness Analysis. 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCV44, 19 May 2018. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/82011?pdfid=53786.

  2. Nicholson G, et al. Hospital Budget Impact Analysis for Giapreza in the Treatment of Severe Distributive Shock in the Intensive Care Unit. 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCV29, 19 May 2018. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/82018?pdfid=53788.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Giapreza cost effective for severe distributive shock. PharmacoEcon Outcomes News 805, 19 (2018). https://doi.org/10.1007/s40274-018-5021-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5021-0

Search

Navigation